Skip to main content
17 January 2021
Last updated:
Saturday 16 January 2021

User account menu

  • Log in
  • Register & Subscribe

Search this site:

 

Primary links

  • Home
  • News
  • About MedNous
  • Research Directory
  • Contact Us

Antibody Drug Conjugates ADCs

The linker matters in antibody-drug conjugates

Sunday 22 November 2020
Interviewee/Contributor
Philipp Spycher
Organisation
Araris Biotech AG
Antibody Drug Conjugates ADCs
Cancer (Oncology)
Drug discovery
  • Read more about The linker matters in antibody-drug conjugates

The US continues to lead in oncology approvals

Sunday 19 January 2020
Interviewee/Contributor
Bruno Pagliara
Organisation
MedNous
Antibody Drug Conjugates ADCs
Cancer (Oncology)
Clinical trials
Immunotherapy
Policy & Regulation
  • Read more about The US continues to lead in oncology approvals

Revisiting antibody-drug conjugates

Tuesday 20 August 2019
Interviewee/Contributor
Chris Martin
Organisation
ADC Therapeutics SA
Antibody Drug Conjugates ADCs
Drug discovery
Strategy
  • Read more about Revisiting antibody-drug conjugates

Targeting new medicines at Roche

Sunday 12 January 2014
Interviewee/Contributor
Max Hasmann
Organisation
Roche Group
Antibody Drug Conjugates ADCs
Cancer (Oncology)
Personalised medicine
Breast cancer
  • Read more about Targeting new medicines at Roche

The inventive step: antibody-drug conjugates

Monday 8 April 2013
Interviewee/Contributor
John Lambert
Organisation
ImmunoGen Inc
Cancer (Oncology)
Antibody Drug Conjugates ADCs
  • Read more about The inventive step: antibody-drug conjugates

Antibodies and ADCs lead cancer pipeline

Saturday 19 May 2012
Interviewee/Contributor
Bruno Pagliara
Organisation
On-Kos Pharma Consulting
Antibody
Antibody Drug Conjugates ADCs
Cancer (Oncology)
  • Read more about Antibodies and ADCs lead cancer pipeline

ADCs propelled back into the oncology spotlight

Monday 14 November 2011
Interviewee/Contributor
Karen Finn
Organisation
MedNous
Antibody Drug Conjugates ADCs
  • Read more about ADCs propelled back into the oncology spotlight

Why Oxford BioTherapeutics is targeting ADCs

Sunday 13 November 2011
Interviewee/Contributor
Christian Rohlff
Organisation
Oxford BioTherapeutics Ltd
Antibody Drug Conjugates ADCs
  • Read more about Why Oxford BioTherapeutics is targeting ADCs

How developers approach antibody drug conjugates

Saturday 12 November 2011
Interviewee/Contributor
Bruno Pagliara
Organisation
On-kòs Pharma Consulting
Cancer (Oncology)
Antibody Drug Conjugates ADCs
Hodkin's Lymphoma
  • Read more about How developers approach antibody drug conjugates
Subscribe to Antibody Drug Conjugates ADCs

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

Klaas Zuideveld becomes CEO of Versameb
Saturday January 16 2021
MorphoSys appoints new CFO
Thursday January 7 2021
Sam Herbert becomes COO at Clinigen
Wednesday January 6 2021
Wolfgang Baiker becomes CEO at Adrenomed
Wednesday January 6 2021
Alligator Bioscience appoints new CMO
Tuesday December 29 2020

© 2021 Evernow Publishing Ltd. Powered by Drupal.